person · Reporting owner
KENNEY CHRISTOPHER JOHN
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Medical Officer | August 28, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 702 |
Reported balance
After 2026-08-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-28 · Sale · Disposed 6,368 · Balance 702 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. F2: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common SharesSEC Table I · non-derivative | Direct | 2 |
Reported balance
After 2026-08-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-28 · Sale · Disposed 700 · Balance 2 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. F3: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4: The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026.
F2: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 01:59 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 700 | $60.98 | $42,683.62 |
DisclosureSEC source: 0001193125-26-377309 · ownership.xml · nonDerivative · entry 2 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $60.81 to $61.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · balance_after: The number of shares beneficially owned following the reported transactions reflects an upward adjustment of one share from the reporting person's previous Form 4 filed on March 13, 2026, based on updated tax withholding calculations for the transactions described on the previously filed Form 4. Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 01:59 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 6,368 | $60.17 | $383,145.37 |
DisclosureSEC source: 0001193125-26-377309 · ownership.xml · nonDerivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 702 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2026. F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $59.79 to $60.68, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,410 | $55.23 | $77,867.25 |
DisclosureSEC source: 0001193125-26-106727 · ownership.xml · nonDerivative · entry 2 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,069 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionRestricted Share Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-106727 · ownership.xml · derivative · entry 3 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Shares · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · derivative.exercise_date: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · derivative.expiration_date: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 12, 2026 Filed Mar 14, 2026 00:16 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-106727 · ownership.xml · nonDerivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F1 · price: Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 23:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 2,771 | $60.11 | $166,559.27 |
DisclosureSEC source: 0001193125-26-102669 · ownership.xml · nonDerivative · entry 2 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,729 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of PSUs granted on March 11, 2024. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionPerformance Share Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102669 · ownership.xml · derivative · entry 4 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · derivative.exercise_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · derivative.expiration_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantPerformance Share Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102669 · ownership.xml · derivative · entry 3 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Shares · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · shares: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · derivative.exercise_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · derivative.expiration_date: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 23:21 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-102669 · ownership.xml · nonDerivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. F1 · price: Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:54 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-009238 · ownership.xml · derivative · entry 2 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027. Read SEC document |
| January 09, 2026 Filed Jan 9, 2026 23:54 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $42.15 | $0.00 |
DisclosureSEC source: 0001193125-26-009238 · ownership.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 23:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantRestricted Share Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-039021 · ownership.xml · derivative · entry 2 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 23:31 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantShare Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $35.48 | $0.00 |
DisclosureSEC source: 0000950170-25-039021 · ownership.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2035-03-11 F1 · derivative.exercise_date: Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:38 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0000950170-24-030239 · ownership.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-03-10 F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 24, 2023 Filed Mar 24, 2023 23:18 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 700 | $35.01 | $24,507.00 |
DisclosureSEC source: 0001209191-23-021136 · doc4.xml · nonDerivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:32 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $34.18 | $0.00 |
DisclosureSEC source: 0001209191-23-018476 · doc4.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 120,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:13 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018449 · doc4.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| January 21, 2022 Filed Jan 21, 2022 22:04 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Shares | 700 | $28.81 | $20,167.00 |
DisclosureSEC source: 0001209191-22-004460 · doc4.xml · nonDerivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:12 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $16.64 | $0.00 |
DisclosureSEC source: 0001209191-21-053304 · doc4.xml · derivative · entry 1 KENNEY CHRISTOPHER JOHN · CIK 0001880129 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2031-08-22 F1 · derivative.exercise_date: Vesting 25% on the one year anniversary of the grant date, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.